Compare INGR & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INGR | TFX |
|---|---|---|
| Founded | 1906 | 1943 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.8B |
| IPO Year | 1997 | 1994 |
| Metric | INGR | TFX |
|---|---|---|
| Price | $104.74 | $138.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | $128.57 | ★ $138.75 |
| AVG Volume (30 Days) | ★ 600.8K | 581.2K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.94% | 1.02% |
| EPS Growth | ★ 15.14 | N/A |
| EPS | ★ 4.01 | 2.08 |
| Revenue | ★ $7,219,000,000.00 | $1,992,713,000.00 |
| Revenue This Year | $3.86 | $15.97 |
| Revenue Next Year | $2.95 | $5.15 |
| P/E Ratio | ★ $26.19 | $67.39 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $94.44 | $100.18 |
| 52 Week High | $130.48 | $145.00 |
| Indicator | INGR | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 53.92 | 57.16 |
| Support Level | $98.04 | $128.36 |
| Resistance Level | $106.46 | $145.00 |
| Average True Range (ATR) | 1.55 | 3.66 |
| MACD | -0.05 | 0.31 |
| Stochastic Oscillator | 41.73 | 87.91 |
Ingredion is an ingredients provider for the food, beverage, brewing, and animal nutrition industries. The company processes corn, tapioca, potatoes, stevia, grains, fruits, gums, and vegetables into value-added ingredients. The company sells specialty ingredients that include starch-based texturizers and natural alternative sweeteners such as stevia. Ingredion also sells commodity ingredients that include sweeteners, such as high-fructose corn syrup, and starches, such as those used for sustainable packaging, as well as plant-based proteins. The company plans to acquire Tate & Lyle in an all-cash deal that should close in 2027.
Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.